Related Experiment Videos
[Chemoembolization for liver metastasis from colorectal cancer]
Y Sasaki1, S Imaoka, S Masutani
1Dept. of Surgery, Center for Adult Diseases, Osaka.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1990
Summary
Transarterial chemoembolization (TCE) shows promise for treating liver metastasis from colorectal cancer. TCE improved survival rates in patients with non-resectable tumors and those with intrahepatic recurrences after surgery.
Area of Science:
- Oncology
- Interventional Radiology
Context:
- Colorectal cancer frequently metastasizes to the liver.
- Treatment options for liver metastasis include surgery and chemotherapy.
- Transarterial chemoembolization (TCE) is an option for liver tumors.
Purpose:
- To evaluate the efficacy of modified sandwich therapy using Lipiodol, cisplatin, angiotensin II, and Gelfoam (TCE) for liver metastasis from colorectal cancer.
Summary:
- Ten patients with resectable liver metastasis received preoperative TCE; 3-year survival was 66% vs. 44% without TCE (not significant).
- Twenty-two non-resectable patients receiving TCE plus intra-arterial chemotherapy had significantly better 1-year survival (545 days median survival) than those receiving chemotherapy alone (285 days median survival).
- Fourteen patients with intrahepatic recurrence after resection receiving TCE showed improved 1-year survival (615 days median survival) compared to those without TCE (190 days median survival).
Impact:
- TCE appears to be an effective treatment modality for liver metastasis from colorectal cancer, particularly for non-resectable cases and intrahepatic recurrences.
- The findings suggest TCE can improve survival outcomes in patients with advanced colorectal cancer liver disease.
- Further research may establish TCE as a standard treatment in specific patient populations with colorectal liver metastasis.